<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148068">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013687</url>
  </required_header>
  <id_info>
    <org_study_id>FhCMB Pfs25-001</org_study_id>
    <nct_id>NCT02013687</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraunhofer, Center for Molecular Biotechnology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraunhofer, Center for Molecular Biotechnology</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, dose escalation, first-in-human study designed primarily to
      evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel
      adjuvant
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>420 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pfs25 VLP- FhCMB</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating female aged 18 - 50 years inclusive

          -  Able to give written informed consent obtained prior to screening

          -  Healthy, as determined by medical history, physical examination, vital signs,  and
             clinical safety laboratory examinations at baseline

          -  Women of childbearing potential must have a negative urine pregnancy test within 24
             hours preceding receipt of each dose.

          -  Females should fulfill one of the following criteria:

               1. At least one year post-menopausal

               2. Surgically sterile

               3. Willing to use oral, implantable, transdermal or injectable  contraceptives for
                  30 days prior to first vaccination and then for the study duration

               4. Willing to abstain from sexual intercourse or use another reliable form of
                  contraception approved by the Investigator (e.g., intrauterine device (IUD),
                  female condom, diaphragm with spermicide, cervical cap, use of condom by the
                  sexual partner or a sterile sexual partner) for 30 days prior to first
                  vaccination through 9 months after third vaccination

          -  Comprehension of the study requirements, as demonstrated by achieving a score of at
             least 80% correct on a short multiple-choice quiz.

               -  Individuals who fail to achieve a passing score on the initial comprehension
                  assessment will be given the opportunity to retest after a review of protocol
                  information.

               -  Individuals who fail the comprehension assessment for the second time will not
                  be enrolled.

          -  Available and able to participate in all planned study visits and procedures.

        Exclusion Criteria:

          -  History of malaria or previous receipt of an investigational malaria vaccine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Bart, MD</last_name>
      <phone>240-238-4953</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
